Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...

S anofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

CHICAGO — Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung function with dupilumab compared with omalizumab, according to a ...

Please provide your email address to receive an email when new articles are posted on . 45.2% of patients who had “nasal allergies” had chronic rhinosinusitis. Patients with CRS tended to be older ...

CINCINNATI (WKRC) -New research on chronic sinus problems could help people with allergies get the correct treatment. As upper respiratory symptoms keep making people feel sick, this study found that ...

Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...